The China-based cancer drug developer’s offering will fund testing of medicines for several blood malignancies — one of which is part of an alliance with Takeda.
New documents clarify how the FDA plans to regulate AI-enabled devices, experts say, but several important questions remain ...
The Senate Finance Committee will meet on Jan. 29 to discuss the confirmation of RFK Jr., whose stances on vaccines and abortion have raised questions from Democrats and Republicans alike.
In an interview, the CEO discussed trying to gain support from investors hyper-focused on M&A, and competing with Pfizer and ...
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.
CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...
The biotech said it has dosed the first participant in a Phase 3 study of its in vivo gene editing treatment. Elsewhere, the FDA imposed a hold on Atara and lifted another on Amylyx.
The rescinded Biden-era orders include actions to boost the Affordable Care Act exchanges, coordinate the government’s ...
The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...
The University of New Hampshire Franklin Pierce School of Law is expanding its focus on specialized legal education with the ...
The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...
Four of the top 10 drugs by prescription sales in 2025 will be from the new incretin class, according to the latest analysis by Evaluate. Consensus forecasts for Ozempic, Wegovy, Mounjaro and Zepbound ...